Skip to main content

Table 2 Commercially available LPAs for TB detection in clinical specimens

From: Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation

Assay

Manufacturer

Method

Material

Sensitivity,% (95% CI)

Specificity,% (95% CI)

References

INNO-LiPA Rif.TB

InnoGenetics, Gent, Belgium

PCR amplification/hybridization

DNA from decontaminated smear-positive sputum

93.0 (92.0 to 94.0)

83.0 (81.0 to 85.0)

[29, 30]

INNO-LiPA Rif.TB

InnoGenetics, Gent, Belgium

PCR amplification/hybridization

DNA from decontaminated smear-negative sputum

65.0 (58.0 to 71.0)

96.0 (94.0 to 97.0)

[29–32]

Hain GT MTBDRplus

Hain Lifescience GbmH, Nehren, Germany

PCR amplification/hybridization

DNA from decontaminated sputum

92.0 (90.0 to 94.0)

-

[33, 34]

  1. CI, confidence interval; LPA, line-probe assay.